In this insightful new interview, key opinion leader Talha Munir reviews the current landscape of chronic lymphocytic leukaemia (CLL), and delves into interim analysis results from the AMPLIFY study with acalabrutinib–venetoclax ± obinutuzumab, 5-year data from the SEQUOIA study with zanubrutinib, and updated data from the BRUIN CLL-321 study with pirtobrutinib.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles


